US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

KraneShares MSCI All China Health Care Index ETF

17.74

-0.0600-0.34%

Post-market: 17.800.0600+0.34%19:30 EDT

Volume:28.78K

Turnover:509.79K

Market Cap:104.67M

PE:- -

High:17.93

Open:17.89

Low:17.60

Close:17.80

52wk High:21.50

52wk Low:14.38

Shares:5.90M

Float Shares:5.90M

Volume Ratio:0.55

T/O Rate:0.49%

Dividend:0.71

Dividend Rate:4.03%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

WuXi Biologics FY26 H1 Net Profit Rises 5.8% to RMB 2.92 Billion; Revenue Increases 18.4% to RMB 11.79 Billion

WuXi Biologics H1 Net Income Attributable RMB 2,439.8 Million

THOMSON REUTERS

Wuxi Biologics (Cayman) Stock Rallies 7.4% in Hong Kong

HK-Listed WuXi XDC Hits 10-Month Peak on Solid First-Half Results

Hong Kong Stocks in Focus: CRO Sector Rallies as Offshore CXO Leaders Post Strong Results

Transcenta Holding Announces Extraordinary General Meeting

Chinese Drugmaker Wuxi XDC's First-Half Revenue Rises on Project Expansion, Acquisition

WuXi XDC FY26 H1 Net Profit Rises 9.7% to RMB 818 Million; Revenue Climbs 37% to RMB 3.7 Billion

Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy

MT Newswires Live

CSPC Pharmaceutical Group Stock Climbs 2.2% in Hong Kong, Outperforms Competitors

Wuxi Biologics (Cayman) Stock Falls 4.7% in Hong Kong

Daiwa Raises CSPC Pharma Target Price to HK$11.2 on In-Line Interim Results

BofA Securities Lifts CSPC Pharma Target Price to HK$8.6 While Maintaining Underperform Rating

UBS Lifts CSPC Pharma Price Target to HK$11.80, Reiterates Buy Rating

Goldman Sachs Adjusts CSPC Pharma Target Price Upward While Retaining Buy Stance

CSPC Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Simply Wall St.

China's Haohai Biological H1 Revenue Falls, Partly Hurt by End of Brighten Optix Distribution

TOT Biopharm FY26 H1 Net Loss Swings to RMB 59 Million; Revenue Drops 49.7% to RMB 246 Million

UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50

MT Newswires Live

Goldman Sachs Raises CSPC Pharma Price Target to HK$12.56, Reaffirms Buy Rating

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrnest.com/stock/KURE/news?page=8"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"KURE","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","market":"US","secType":"STK","nameCN":"KraneShares MSCI All China Health Care Index ETF","latestPrice":17.74,"timestamp":1789156800000,"preClose":17.8,"halted":0,"volume":28778,"hourTrading":{"tag":"盘后","latestPrice":17.8,"preClose":17.74,"latestTime":"19:30 EDT","volume":110,"amount":1957.48,"timestamp":1789169406504,"change":0.06,"changeRate":0.003382,"amplitude":0.003382},"delay":0,"changeRate":-0.00337078651685406,"floatShares":5900168,"shares":5900168,"eps":0,"marketStatus":"Market Closed","change":-0.06,"latestTime":"09-11 16:00:00 EDT","open":17.89,"high":17.93,"low":17.6,"amount":509789.147232,"amplitude":0.018539,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789372800000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":17.8,"sharesOutstanding":4750002,"nav":17.98,"aum":106101372.73,"dividendRate":0.040293,"bidAskSpread":0.008302,"postHourTrading":{"tag":"盘后","latestPrice":17.8,"preClose":17.74,"latestTime":"19:30 EDT","volume":110,"amount":1957.48,"timestamp":1789169406504,"change":0.06,"changeRate":0.003382,"amplitude":0.003382},"volumeRatio":0.5515710695008692,"impliedVol":0.3113,"impliedVolPercentile":0.6295},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"KURE\",,,,,undefined,":{"symbol":"KURE","floatShares":5900168,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.5515710695008692,"shares":5900168,"dividePrice":0.7148,"high":17.93,"amplitude":0.018539,"preClose":17.8,"low":17.6,"week52Low":14.3797,"pbRate":"--","week52High":21.5,"institutionHeld":0,"latestPrice":17.74,"eps":0,"divideRate":0.040293,"volume":28778,"delay":0,"ttmEps":0,"open":17.89,"prevYearClose":17.04,"prevWeekClose":18.9,"prevMonthClose":18.54,"prevQuarterClose":15.747,"fiveDayClose":18.91,"twentyDayClose":18.66,"sixtyDayClose":14.875},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/KURE\",params:#limit:5,,,undefined,":[{"date":"2025-12-22","symbol":"KURE","amount":0.714689,"announcedDate":"2025-12-19","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-12-22","defaultRemindTime":1766413800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-12-23","payableDate":"2025-12-22","currency":"USD","dateTimestamp":1766379600000,"payDate":"2025-12-23"},{"date":"2024-12-17","symbol":"KURE","amount":0.18361,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-17","defaultRemindTime":1734445800000,"name":"KraneShares MSCI All China Health Care Index ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-18","payableDate":"2024-12-17","currency":"USD","dateTimestamp":1734411600000,"payDate":"2024-12-18"},{"date":"2023-12-18","symbol":"KURE","amount":0.112844,"announcedDate":"2023-12-15","type":"dividend","market":"US","newRecordDate":"2023-12-19","defaultRemindTime":1702909800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2023-12-20","payableDate":"2023-12-19","currency":"USD","dateTimestamp":1702875600000,"payDate":"2023-12-20"},{"market":"US","date":"2022-12-28","symbol":"KURE","amount":0.010399,"defaultRemindTime":1672237800000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2022-12-30","payableDate":"2022-12-29","currency":"USD","type":"dividend","dateTimestamp":1672203600000},{"market":"US","date":"2021-12-29","symbol":"KURE","amount":4.053448,"defaultRemindTime":1640788200000,"name":"KraneShares MSCI All China Health Care Index ETF","recordDate":"2021-12-31","payableDate":"2021-12-30","currency":"USD","type":"dividend","dateTimestamp":1640754000000}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"KURE\",market:\"US\",,,undefined,":[{"executeDate":"2018-12-26","recordDate":"2018-12-27","paymentDate":"2018-12-28","value":0.039344,"currency":"USD"},{"executeDate":"2019-12-27","recordDate":"2019-12-30","paymentDate":"2019-12-31","value":0.057325,"currency":"USD"},{"executeDate":"2020-12-29","recordDate":"2020-12-30","paymentDate":"2020-12-31","value":0.000109,"currency":"USD"},{"executeDate":"2021-12-29","recordDate":"2021-12-30","paymentDate":"2021-12-31","value":4.053448,"currency":"USD"},{"executeDate":"2022-12-28","recordDate":"2022-12-29","paymentDate":"2022-12-30","value":0.010399,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"KURE\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"KURE\",pageSize:20,pageCount:8,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2662384547","title":"WuXi Biologics FY26 H1 Net Profit Rises 5.8% to RMB 2.92 Billion; Revenue Increases 18.4% to RMB 11.79 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2662384547","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662384547?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:52","pubTimestamp":1787651566,"startTime":"0","endTime":"0","summary":"WuXi Biologics FY26 H1 net profit rises 5.8% to RMB 2.92 billion; revenue increases 18.4% to RMB 11.79 billionWuxi Biologics posted revenue of RMB 11.79 billion, up 18.4% year-on-year, in the six months ended June 30, 2026.Net profit rose 5.8% to RMB 2.92 billion; diluted EPS increased 5.5% to RMB 0.58.Gross profit climbed 28.1% to RMB 5.45 billion; gross margin widened 3.5 percentage points to 46.2%.Adjusted EBITDA  increased to RMB 5.38 billion from RMB 4.31 billion; adjusted EBITDA margin expanded to 45.6% from 43.3%.Backlog reached US$25.1 billion; integrated projects totaled 1,064, with late-phase projects at 78 and commercial manufacturing at 28.Disclaimer:This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wuxi Biologics  Inc. published the ori","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nNDLNqh98:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359202008.SGD","LU0823426480.USD","BK1521","LU0856984785.SGD","LU0516422440.USD","LU0979878070.USD","SG9999002463.SGD","LU0823426308.USD","LU0348735423.USD","LU0051755006.USD","02269","LU0181495838.USD","LU0516423174.USD","SG9999002562.SGD","LU0307460666.USD","IE00B0JY6N72.USD","LU1242518857.USD","BK1610","LU0140636845.USD","LU0516422952.EUR","LU0128526141.USD","LU0456827905.SGD","LU0417516902.SGD","LU0572944931.SGD","LU0043850808.USD","LU1720050803.USD","LU0516422366.SGD","BK1589","LU0326950275.SGD","LU1794554557.SGD","LU0819121731.USD","LU0359201612.USD","BK1576","LU0052750758.USD","LU0417516738.SGD","LU0029874061.USD","LU2039709279.SGD","LU1880383366.USD","LU1688375341.USD","LU1242518931.SGD","KURE","BK1141","LU0327786744.USD","LU3063872942.SGD","LU0708995583.HKD","LU0039217434.USD","LU0320764599.SGD","LU0516423091.SGD","LU0588546209.SGD","LU0456846285.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662738466","title":"WuXi Biologics H1 Net Income Attributable RMB 2,439.8 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2662738466","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662738466?lang=en_us&edition=fundamental","pubTime":"2026-08-25 17:52","pubTimestamp":1787651564,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nPLX77S9DS:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU1880383366.USD","LU1720050803.USD","LU0516423091.SGD","LU0516423174.USD","LU0572944931.SGD","LU0708995583.HKD","LU0326950275.SGD","LU1794554557.SGD","LU1242518931.SGD","LU0043850808.USD","IE00B0JY6N72.USD","LU0140636845.USD","LU0359202008.SGD","LU0456846285.SGD","LU0320764599.SGD","LU0823426308.USD","BK1521","LU0128526141.USD","BK1589","LU0181495838.USD","LU0348735423.USD","LU0516422366.SGD","LU0516422952.EUR","LU3063872942.SGD","SG9999002463.SGD","BK1610","LU0307460666.USD","SG9999002562.SGD","LU0823426480.USD","BK1576","LU0588546209.SGD","LU0856984785.SGD","LU0979878070.USD","LU1688375341.USD","LU0359201612.USD","02269","LU0417516738.SGD","LU0819121731.USD","BK1141","LU0052750758.USD","LU0051755006.USD","KURE","LU0516422440.USD","LU2039709279.SGD","LU0456827905.SGD","LU0327786744.USD","LU0029874061.USD","LU0417516902.SGD","LU0039217434.USD","LU1242518857.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662782933","title":"Wuxi Biologics (Cayman) Stock Rallies 7.4% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2662782933","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662782933?lang=en_us&edition=fundamental","pubTime":"2026-08-25 16:31","pubTimestamp":1787646660,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. rallied 7.4% to 52.20 Hong Kong dollars , on what proved to be an all-around mediocre trading session for the Hong Kong stock market, with the Hang Seng Index remaining mostly flat at 25511.10.Wuxi Biologics  Inc. hit a new 52-week high, surpassing its previous peak of HK$51.55, which the company reached Aug. 20.Trading volume totaled 60.1 million shares, compared to the 50-day average of 35.2 million shares.Data source: Dow Jones Market Data, FactSet","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0348825331.USD","LU0043850808.USD","LU0708995583.HKD","LU1794554557.SGD","LU1720050803.USD","LU0823426308.USD","LU0029874061.USD","LU0326950275.SGD","LU0823426480.USD","LU1688375341.USD","LU0456827905.SGD","LU2039709279.SGD","BK1610","SG9999002562.SGD","LU0181495838.USD","LU0516422440.USD","LU3063872942.SGD","BK1589","LU0417516902.SGD","LU0516422952.EUR","LU0572944931.SGD","LU0588546209.SGD","LU1880383366.USD","LU0128526141.USD","LU0516423174.USD","KURE","BK1576","LU0348735423.USD","LU0516422366.SGD","SG9999002463.SGD","BK1521","LU0051755006.USD","LU0417516738.SGD","LU0039217434.USD","LU0456846285.SGD","LU0856984785.SGD","LU0052750758.USD","LU0327786744.USD","LU1242518857.USD","LU0320764599.SGD","LU0516423091.SGD","LU0140636845.USD","02269","LU1242518931.SGD","IE00B0JY6N72.USD","LU0307460666.USD","LU0359201612.USD","LU0979878070.USD","LU0359202008.SGD","LU0819121731.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662788822","title":"HK-Listed WuXi XDC Hits 10-Month Peak on Solid First-Half Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2662788822","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662788822?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:44","pubTimestamp":1787625894,"startTime":"0","endTime":"0","summary":"BUZZ-HK-listed WuXi XDC hits 10-month peak on solid first-half results** Shares of Chinese drugmaker WuXi XDC2268.HKjump 12% to HK$78.2, their highest point since October 9, 2025** Stock posts its big","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260825:nL1N44M01G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0181495838.USD","LU0588546209.SGD","LU0456846285.SGD","LU0052750758.USD","LU0140636845.USD","LU0516423174.USD","LU0979878070.USD","SG9999002562.SGD","IE00B0JY6N72.USD","LU0029874061.USD","LU0417516738.SGD","LU0708995583.HKD","LU0823426480.USD","LU0516422952.EUR","LU1242518857.USD","LU0359201612.USD","LU1688375341.USD","LU0348735423.USD","LU1794554557.SGD","LU0307460666.USD","LU3063872942.SGD","LU0417516902.SGD","SG9999002463.SGD","BK1610","02269","LU0516423091.SGD","LU1242518931.SGD","LU0359202008.SGD","LU2039709279.SGD","LU1880383366.USD","BK1141","BK1521","BK1589","LU0516422440.USD","LU0516422366.SGD","KURE","LU0856984785.SGD","BK1576","02268","LU0572944931.SGD","SG9999014674.SGD","LU0051755006.USD","LU0320764599.SGD","LU0456827905.SGD","LU0819121731.USD","LU0327786744.USD","LU0039217434.USD","LU0823426308.USD","LU0348825331.USD","LU0043850808.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1190498853","title":"Hong Kong Stocks in Focus: CRO Sector Rallies as Offshore CXO Leaders Post Strong Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1190498853","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1190498853?lang=en_us&edition=fundamental","pubTime":"2026-08-25 10:24","pubTimestamp":1787624657,"startTime":"0","endTime":"0","summary":"Shares of contract research organization (CRO) companies are leading gains in Hong Kong trading, driven by a wave of better-than-expected earnings from global CXO industry leaders that underscores a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1610","LU1880383366.USD","SG9999002463.SGD","06821","HK0000320264.USD","LU0039217434.USD","LU1242518857.USD","LU1242518931.SGD","LU2039709279.SGD","WX","03347","BK1191","LU0819121731.USD","LU0307460666.USD","LU0348735423.USD","LU0979878070.USD","LU0516422952.EUR","LU1794554557.SGD","LU0516423091.SGD","BK1141","LU0359201612.USD","LU0456827905.SGD","LU0823426308.USD","02269","BK1521","LU0327786744.USD","LU0588546209.SGD","LU0052750758.USD","HK0000306701.USD","KURE","LU0051755006.USD","LU0359202008.SGD","LU0320764599.SGD","BK1583","LU0348825331.USD","BK4585","LU0417516738.SGD","LU0417516902.SGD","LU0856984785.SGD","HK0000306685.HKD","CXO","IE00B0JY6N72.USD","LU1720050803.USD","LU0181495838.USD","LU0326950275.SGD","VXUS","LU3063872942.SGD","HK0000320223.HKD","BK1589","LU0029874061.USD","LU0572944931.SGD","LU0823426480.USD","LU1688375341.USD","LU0516422366.SGD","BK1576","BK4588","LU0043850808.USD","LU0456846285.SGD","LU0516423174.USD","LU0128526141.USD","LU0140636845.USD","LU0708995583.HKD","KCAI","01548","SG9999002562.SGD","LU0516422440.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662875201","title":"Transcenta Holding Announces Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2662875201","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662875201?lang=en_us&edition=fundamental","pubTime":"2026-08-25 06:06","pubTimestamp":1787609194,"startTime":"0","endTime":"0","summary":"Transcenta Holding announces extraordinary general meetingTranscenta will hold an extraordinary general meeting in Suzhou, China on Sept. 9, 2026.Shareholders will vote on a major disposal of CDMO ass","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL4Yyp1L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999002463.SGD","LU0588546209.SGD","LU0516423174.USD","LU0051755006.USD","LU0572944931.SGD","LU0307460666.USD","LU0359202008.SGD","LU0348825331.USD","LU0823426308.USD","LU0140636845.USD","LU0819121731.USD","LU0456846285.SGD","LU0327786744.USD","LU0516422440.USD","BK1610","BK1521","LU0708995583.HKD","LU3063872942.SGD","LU0823426480.USD","LU1242518857.USD","LU0516422952.EUR","LU1688375341.USD","BK1161","LU0039217434.USD","LU0417516738.SGD","LU1794554557.SGD","BK1576","06628","LU0326950275.SGD","LU0516423091.SGD","LU0348735423.USD","BK1589","KURE","LU0043850808.USD","LU0052750758.USD","LU0516422366.SGD","IE00B0JY6N72.USD","LU0456827905.SGD","LU0417516902.SGD","SG9999002562.SGD","LU1880383366.USD","02269","LU0856984785.SGD","LU0029874061.USD","LU0359201612.USD","BK1141","LU0128526141.USD","LU0181495838.USD","LU2039709279.SGD","LU1720050803.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661512275","title":"Chinese Drugmaker Wuxi XDC's First-Half Revenue Rises on Project Expansion, Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2661512275","media":"Reuters","labels":["corporation","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661512275?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:34","pubTimestamp":1787571262,"startTime":"0","endTime":"0","summary":"Chinese drugmaker Wuxi XDC's first-half revenue rises on project expansion, acquisitionOverviewChina bioconjugate CRDMO's H1 2026 revenue grew 37% yr/yr to RMB3.7 blnAdjusted net profit for H1 2026 ro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nL1N44L0D5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0359201612.USD","688428","LU2039709279.SGD","SG9999014674.SGD","LU0456827905.SGD","LU0588546209.SGD","BK1141","BK1589","BK1230","00656","02696","LU1720050803.USD","SG9999002562.SGD","IE00B0JY6N72.USD","LU0348735423.USD","BK1576","LU0140636845.USD","LU0051755006.USD","LU0417516902.SGD","LU0359202008.SGD","02269","BK1610","LU1688375341.USD","LU0029874061.USD","LU0516422440.USD","HK0000306701.USD","LU2488822045.USD","LU1794554557.SGD","LU0320764599.SGD","LU0708995583.HKD","LU0456846285.SGD","HK0000306685.HKD","LU0326950275.SGD","LU0572944931.SGD","LU0856984785.SGD","LU1880383366.USD","LU1242518857.USD","LU0819121731.USD","HK0000320223.HKD","02268","LU0348825331.USD","KURE","LU0516423091.SGD","LU0052750758.USD","LU0327786744.USD","LU0039217434.USD","LU1242518931.SGD","LU3063872942.SGD","BK1161","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273772","title":"WuXi XDC FY26 H1 Net Profit Rises 9.7% to RMB 818 Million; Revenue Climbs 37% to RMB 3.7 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273772","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273772?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:22","pubTimestamp":1787570557,"startTime":"0","endTime":"0","summary":"WuXi XDC FY26 H1 net profit rises 9.7% to RMB 818 million; revenue climbs 37% to RMB 3.7 billionWuxi XDC Cayman posted revenue of RMB 3.7 billion, up 37% year over year, for the six months ended June ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260824:nNDL6G2blf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014674.SGD","LU0051755006.USD","BK1141","LU0307460666.USD","LU0819121731.USD","LU0516422440.USD","LU0348825331.USD","LU0572944931.SGD","LU0140636845.USD","LU0588546209.SGD","BK1521","LU0029874061.USD","BK1610","LU0516423174.USD","LU0516422366.SGD","LU2488822045.USD","LU0348735423.USD","BK1576","LU0128526141.USD","LU0320764599.SGD","LU0516423091.SGD","LU1688375341.USD","LU0979878070.USD","LU0856984785.SGD","LU0043850808.USD","LU0708995583.HKD","LU0823426480.USD","LU0456827905.SGD","LU1880383366.USD","LU0039217434.USD","LU1242518857.USD","LU0052750758.USD","02269","KURE","BK1589","LU2039709279.SGD","LU1242518931.SGD","LU0823426308.USD","SG9999002562.SGD","LU0359202008.SGD","LU0417516738.SGD","02268","LU1720050803.USD","LU0417516902.SGD","LU0359201612.USD","IE00B0JY6N72.USD","LU0327786744.USD","LU0181495838.USD","LU0456846285.SGD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661273445","title":"Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$10.93 From HK$10.31, Keeps at Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2661273445","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661273445?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:12","pubTimestamp":1787569969,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) has an average rating of buy and mean price target of HK$12.33, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic researc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["KURE","HK0000165453.HKD","IE00B031HY20.USD","LU1226287529.USD","LU1951186391.HKD","LU1960683339.HKD","LU1152091168.USD","LU0314109678.HKD","LU1226287875.USD","IE00B5MMRT66.SGD","SG9999004220.SGD","IE0008368742.USD","LU0072913022.USD","BK1521","IE0008369823.USD","LU0067412154.USD","IE00BZ08YR35.GBP","LU1226288170.HKD","IE00BZ08YT58.USD","LU1152091754.HKD","LU0315179316.USD","LU1328277881.USD","LU1226288253.USD","IE00BZ08YS42.EUR","01093","LU1008478684.HKD","LU0880133367.SGD","BK1515","LU1813983027.USD","LU1993786604.SGD","BK1191","LU1807302812.USD","LU2039709279.SGD","LU1226287792.SGD","LU0501845795.SGD","LU0326950275.SGD","LU0140636845.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661497221","title":"CSPC Pharmaceutical Group Stock Climbs 2.2% in Hong Kong, Outperforms Competitors","url":"https://stock-news.laohu8.com/highlight/detail?id=2661497221","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661497221?lang=en_us&edition=fundamental","pubTime":"2026-08-24 16:32","pubTimestamp":1787560320,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of CSPC Pharmaceutical Group Ltd. rose 2.2% to 9.40 Hong Kong dollars on what proved to be an all-around grim trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.9% to 25517.33.CSPC Pharmaceutical Group Ltd. closed 19% short of its 52-week high of HK$11.63, which the company achieved Sept. 9.The stock outperformed some of its competitors, as Sino Biopharmaceutical Ltd. fell 0.3%, SSY Group Ltd. fell 0.4%, and United Laboratories International Holdings Ltd. fell 0.7%.Trading volume totaled 141.6 million shares, compared to the 50-day average of 98.7 million shares.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","LU2039709279.SGD","IE00BZ08YR35.GBP","IE0008368742.USD","LU1951186391.HKD","LU1226288253.USD","LU1960683339.HKD","LU1152091168.USD","LU0072913022.USD","01093","LU0314109678.HKD","LU1226288170.HKD","IE00BZ08YT58.USD","LU1226287529.USD","LU1813983027.USD","IE00B543WZ88.USD","IE00B031HY20.USD","IE00BZ08YS42.EUR","LU0067412154.USD","LU0140636845.USD","LU1328277881.USD","LU1993786604.SGD","LU1152091754.HKD","LU1226287875.USD","IE0008369823.USD","HK0000165453.HKD","LU0501845795.SGD","LU1807302812.USD","LU0315179316.USD","BK1521","LU1226287792.SGD","BK1191","KURE","BK1515","LU0880133367.SGD","LU1008478684.HKD","IE00B5MMRT66.SGD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661221146","title":"Wuxi Biologics (Cayman) Stock Falls 4.7% in Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=2661221146","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661221146?lang=en_us&edition=fundamental","pubTime":"2026-08-24 16:30","pubTimestamp":1787560200,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.Shares of Wuxi Biologics  Inc. slipped 4.7% to 48.60 Hong Kong dollars on what proved to be an all-around dismal trading session for the Hong Kong stock market, with the Hang Seng Index falling 1.9% to 25517.33.The stock's fall snapped a two-day winning streak.Wuxi Biologics  Inc. closed 5.7% below its 52-week high of HK$51.55, which the company achieved Aug. 20.Trading volume totaled 43.8 million shares, compared to the 50-day average of 35.0 million shares.Data source: Dow Jones Market Data, FactSet","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0051755006.USD","LU0307460666.USD","LU0819121731.USD","LU0516422440.USD","SG9999002463.SGD","LU0348825331.USD","LU0572944931.SGD","LU0140636845.USD","LU0588546209.SGD","BK1521","LU0029874061.USD","BK1610","LU0516423174.USD","LU0516422366.SGD","LU3063872942.SGD","LU0348735423.USD","BK1576","LU0128526141.USD","LU0320764599.SGD","LU0516423091.SGD","LU1688375341.USD","LU0979878070.USD","LU0516422952.EUR","LU0856984785.SGD","LU0043850808.USD","LU0708995583.HKD","LU0823426480.USD","LU0456827905.SGD","LU1880383366.USD","LU0039217434.USD","LU1242518857.USD","LU0052750758.USD","02269","KURE","BK1589","LU2039709279.SGD","LU1242518931.SGD","LU0823426308.USD","SG9999002562.SGD","LU0359202008.SGD","LU0417516738.SGD","LU1720050803.USD","LU1794554557.SGD","LU0417516902.SGD","LU0359201612.USD","IE00B0JY6N72.USD","LU0327786744.USD","LU0181495838.USD","LU0456846285.SGD","LU0326950275.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1106235404","title":"Daiwa Raises CSPC Pharma Target Price to HK$11.2 on In-Line Interim Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1106235404","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1106235404?lang=en_us&edition=fundamental","pubTime":"2026-08-24 15:46","pubTimestamp":1787557578,"startTime":"0","endTime":"0","summary":"Daiwa has issued a research report noting that CSPC Pharma (01093) posted a 40.1% year-on-year increase in interim revenue to RMB 18.59 billion, aligning with its earlier business guidance and the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0008369823.USD","LU0067412154.USD","LU2039709279.SGD","LU1226287792.SGD","HK0000165453.HKD","LU1226287875.USD","IE00B5MMRT66.SGD","IE00B031HY20.USD","01093","LU1226288253.USD","IE00B543WZ88.USD","LU0140636845.USD","LU1226288170.HKD","LU1993786604.SGD","LU1152091168.USD","LU0880133367.SGD","SG9999004220.SGD","LU1960683339.HKD","EWH","LU0501845795.SGD","BK1191","LU0072913022.USD","IE00BZ08YT58.USD","LU1813983027.USD","LU1226287529.USD","LU0326950275.SGD","LU1152091754.HKD","IE00BZ08YR35.GBP","LU1328277881.USD","LU1951186391.HKD","LU0314109678.HKD","BK1515","KURE","IE0008368742.USD","LU0315179316.USD","LU1807302812.USD","LU1008478684.HKD","IE00BZ08YS42.EUR","BK1521"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128964959","title":"BofA Securities Lifts CSPC Pharma Target Price to HK$8.6 While Maintaining Underperform Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1128964959","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128964959?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:50","pubTimestamp":1787460626,"startTime":"0","endTime":"0","summary":"BofA Securities has released a research report indicating that CSPC PHARMA (01093) saw its total revenue and attributable net profit surge by 40.1% and 139.2% year-on-year, respectively, reaching RMB...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1152091168.USD","LU0140636845.USD","LU0315179316.USD","LU1807302812.USD","SG9999004220.SGD","LU1226287792.SGD","IE00BZ08YS42.EUR","BK1191","IE00BZ08YR35.GBP","LU0314109678.HKD","HK0000165453.HKD","LU1008478684.HKD","LU1951186391.HKD","LU0072913022.USD","LU0326950275.SGD","BK1521","IE0008368742.USD","LU1226287875.USD","LU2039709279.SGD","IE0008369823.USD","161027","IE00BZ08YT58.USD","EWH","BK1515","LU0067412154.USD","IE00B543WZ88.USD","IE00B5MMRT66.SGD","LU1993786604.SGD","LU0501845795.SGD","01093","LU0880133367.SGD","KURE","LU1328277881.USD","IE00B031HY20.USD","LU1152091754.HKD","LU1960683339.HKD","LU1226288170.HKD","LU1226288253.USD","LU1226287529.USD","LU1813983027.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1110238919","title":"UBS Lifts CSPC Pharma Price Target to HK$11.80, Reiterates Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1110238919","media":"Deep News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110238919?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:40","pubTimestamp":1787460024,"startTime":"0","endTime":"0","summary":"UBS has released a research report reiterating its \"Buy\" rating on CSPC PHARMA (01093) and raising its target price from HK$10.9 to HK$11.8. The adjustment reflects the company's increased R&D...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","LU0072913022.USD","LU1993786604.SGD","BK1521","01093","LU0326950275.SGD","LU1807302812.USD","BK1191","LU1226287529.USD","IE0008368742.USD","LU0880133367.SGD","LU1226288170.HKD","LU1008478684.HKD","LU1226287792.SGD","LU1226287875.USD","IE00BZ08YS42.EUR","IE0008369823.USD","LU1328277881.USD","SG9999004220.SGD","LU1813983027.USD","LU0140636845.USD","LU0501845795.SGD","IE00B543WZ88.USD","LU1960683339.HKD","LU1152091754.HKD","LU1152091168.USD","LU1226288253.USD","HK0000165453.HKD","LU1951186391.HKD","IE00BZ08YT58.USD","LU0315179316.USD","IE00BZ08YR35.GBP","LU0067412154.USD","EWH","LU0314109678.HKD","BK1515","IE00B031HY20.USD","LU2039709279.SGD","IE00B5MMRT66.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162911841","title":"Goldman Sachs Adjusts CSPC Pharma Target Price Upward While Retaining Buy Stance","url":"https://stock-news.laohu8.com/highlight/detail?id=1162911841","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162911841?lang=en_us&edition=fundamental","pubTime":"2026-08-23 12:30","pubTimestamp":1787459445,"startTime":"0","endTime":"0","summary":"Goldman Sachs has released a research note reaffirming its \"Buy\" rating on CSPC Pharma (01093), while raising its profit forecasts for the 2026 to 2028 period by 0.2% to 1.7%. The investment bank has...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KURE","HK0000165453.HKD","IE00B031HY20.USD","LU1226287529.USD","LU1951186391.HKD","LU1960683339.HKD","LU1152091168.USD","LU0314109678.HKD","EWH","LU1226287875.USD","IE00B5MMRT66.SGD","SG9999004220.SGD","IE0008368742.USD","LU0072913022.USD","BK1521","IE0008369823.USD","LU0067412154.USD","IE00BZ08YR35.GBP","LU1226288170.HKD","IE00BZ08YT58.USD","LU1152091754.HKD","LU0315179316.USD","LU1328277881.USD","LU1226288253.USD","IE00BZ08YS42.EUR","01093","LU1008478684.HKD","LU0880133367.SGD","BK1515","LU1813983027.USD","LU1993786604.SGD","BK1191","LU1807302812.USD","LU2039709279.SGD","LU1226287792.SGD","LU0501845795.SGD","LU0326950275.SGD","LU0140636845.USD","IE00B543WZ88.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661217309","title":"CSPC Pharmaceutical Group Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year","url":"https://stock-news.laohu8.com/highlight/detail?id=2661217309","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661217309?lang=en_us&edition=fundamental","pubTime":"2026-08-23 08:56","pubTimestamp":1787446588,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group Limited ( HKG:1093 ) defied analyst predictions to release its half-year results, which were...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-limited-beat-analyst-estimates-see","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-1093/cspc-pharmaceutical-group-shares/news/cspc-pharmaceutical-group-limited-beat-analyst-estimates-see","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU1226287529.USD","KURE","PMDE","IE00BZ08YT58.USD","LU0326950275.SGD","01093","LU0140636845.USD","LU1813983027.USD","IE00B5MMRT66.SGD","LU1226287875.USD","LU0501845795.SGD","LU0067412154.USD","LU1152091168.USD","LU1807302812.USD","LU0315179316.USD","VOTE","LU1008478684.HKD","LU0314109678.HKD","LU0880133367.SGD","LU2039709279.SGD","LU1328277881.USD","DECU","GXDW","BK1521","IE00BZ08YR35.GBP","RGLO","IE00B031HY20.USD","LU1951186391.HKD","LU1226287792.SGD","LU1152091754.HKD","SG9999004220.SGD","BK1515","IE0008369823.USD","VGFPF","IE0008368742.USD","FEBU","LU1960683339.HKD","JOYT","LU1993786604.SGD","HK0000165453.HKD","LU1226288170.HKD","LU0072913022.USD","LU1226288253.USD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661932892","title":"China's Haohai Biological H1 Revenue Falls, Partly Hurt by End of Brighten Optix Distribution","url":"https://stock-news.laohu8.com/highlight/detail?id=2661932892","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661932892?lang=en_us&edition=fundamental","pubTime":"2026-08-21 21:25","pubTimestamp":1787318735,"startTime":"0","endTime":"0","summary":"China's Haohai Biological H1 revenue falls, partly hurt by end of Brighten Optix distributionOverviewChina biomedical products maker's half-year revenue fell 9.8% yr/yr to RMB1.17 blnNet profit attrib","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nL1N44I0EM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1813983027.USD","LU1152091168.USD","LU1951186391.HKD","LU2039709279.SGD","LU0314109678.HKD","IE00B5MMRT66.SGD","LU1993786604.SGD","LU1226288253.USD","BK1593","HK0000165453.HKD","LU1960683339.HKD","LU0067412154.USD","IE00B031HY20.USD","LU1226287875.USD","LU0880133367.SGD","LU0072913022.USD","IE00BZ08YS42.EUR","LU1226288170.HKD","LU0140636845.USD","BK1191","LU1328277881.USD","BK1161","BK1521","LU1152091754.HKD","LU0315179316.USD","LU0501845795.SGD","BK1515","IE00BZ08YR35.GBP","LU1226287792.SGD","SG9999004220.SGD","LU1807302812.USD","IE00B543WZ88.USD","688366","IE0008368742.USD","BK0251","01093","LU0326950275.SGD","06826","LU1226287529.USD","BK0239","LU1008478684.HKD","KURE","IE00BZ08YT58.USD","IE0008369823.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661260315","title":"TOT Biopharm FY26 H1 Net Loss Swings to RMB 59 Million; Revenue Drops 49.7% to RMB 246 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2661260315","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661260315?lang=en_us&edition=fundamental","pubTime":"2026-08-21 19:47","pubTimestamp":1787312862,"startTime":"0","endTime":"0","summary":"TOT Biopharm FY26 H1 net loss swings to RMB 59 million; revenue drops 49.7% to RMB 246 millionTOT BioPharm posted a net loss of RMB 59 million for the six months ended June 30, swinging from profit.Re","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260821:nNDL4m4SR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0327786744.USD","LU0819121731.USD","LU1880383366.USD","LU0348825331.USD","BK1521","LU0823426308.USD","LU0326950275.SGD","LU1794554557.SGD","BK1576","LU0359201612.USD","LU0516423091.SGD","LU1720050803.USD","LU0140636845.USD","LU0516422952.EUR","LU0588546209.SGD","SG9999002562.SGD","LU0052750758.USD","LU0039217434.USD","LU0307460666.USD","BK1161","BK1589","LU0417516738.SGD","LU0516422440.USD","KURE","LU0417516902.SGD","LU0856984785.SGD","LU0456846285.SGD","BK1574","LU0029874061.USD","LU0320764599.SGD","LU0051755006.USD","LU0823426480.USD","02269","LU0359202008.SGD","LU1242518931.SGD","LU0516422366.SGD","LU3063872942.SGD","LU0181495838.USD","LU0456827905.SGD","LU0043850808.USD","IE00B0JY6N72.USD","LU1242518857.USD","LU1688375341.USD","LU0348735423.USD","LU0516423174.USD","LU0572944931.SGD","LU0979878070.USD","SG9999002463.SGD","LU0128526141.USD","01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661646202","title":"UOB Kay Hian Upgrades CSPC Pharmaceutical Group to Buy from Sell; Price Target is HK$11.50","url":"https://stock-news.laohu8.com/highlight/detail?id=2661646202","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661646202?lang=en_us&edition=fundamental","pubTime":"2026-08-21 18:26","pubTimestamp":1787307972,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group (HKG:1093) has an average rating of overweight and mean price target of HK$12.07, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1152091168.USD","IE00BZ08YR35.GBP","BK1521","IE0008369823.USD","LU1993786604.SGD","BK1515","LU0326950275.SGD","IE00B543WZ88.USD","IE00BZ08YS42.EUR","LU1813983027.USD","LU1807302812.USD","LU1226287792.SGD","LU0067412154.USD","LU1226287529.USD","LU1951186391.HKD","LU1226288170.HKD","LU1152091754.HKD","IE0008368742.USD","LU0315179316.USD","LU1226288253.USD","SG9999004220.SGD","HK0000165453.HKD","IE00BZ08YT58.USD","BK1191","KURE","LU1960683339.HKD","IE00B5MMRT66.SGD","LU0314109678.HKD","LU0072913022.USD","LU0140636845.USD","01093","LU0880133367.SGD","LU1226287875.USD","LU1328277881.USD","LU2039709279.SGD","IE00B031HY20.USD","LU0501845795.SGD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1191293609","title":"Goldman Sachs Raises CSPC Pharma Price Target to HK$12.56, Reaffirms Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=1191293609","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191293609?lang=en_us&edition=fundamental","pubTime":"2026-08-21 17:20","pubTimestamp":1787304047,"startTime":"0","endTime":"0","summary":"Goldman Sachs has released a research report reaffirming its \"Buy\" rating on CSPC Pharma (01093), while lifting the target price from HK$12.14 to HK$12.56. The firm has also raised its earnings...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0326950275.SGD","LU2039709279.SGD","IE00BZ08YR35.GBP","IE0008368742.USD","LU1951186391.HKD","LU1226288253.USD","LU1960683339.HKD","LU1152091168.USD","LU0072913022.USD","01093","LU0314109678.HKD","LU1226288170.HKD","IE00BZ08YT58.USD","LU1226287529.USD","LU1813983027.USD","IE00B543WZ88.USD","IE00B031HY20.USD","IE00BZ08YS42.EUR","LU0067412154.USD","LU0140636845.USD","LU1328277881.USD","LU1993786604.SGD","LU1152091754.HKD","EWH","LU1226287875.USD","IE0008369823.USD","HK0000165453.HKD","LU0501845795.SGD","LU1807302812.USD","BK1521","LU0315179316.USD","LU1226287792.SGD","BK1191","KURE","BK1515","LU0880133367.SGD","LU1008478684.HKD","IE00B5MMRT66.SGD","SG9999004220.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":8,"totalSize":200,"code":"91000000","status":"200"}]}}